Synonym
Nufenoxole; Nufenoxolum; SC 27166; SC-27166; SC27166;
IUPAC/Chemical Name
2-(3-(2-azabicyclo[2.2.2]octan-2-yl)-1,1-diphenylpropyl)-5-methyl-1,3,4-oxadiazole
InChi Key
CVOCKGAVXLCEGM-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H29N3O/c1-19-26-27-24(29-19)25(21-8-4-2-5-9-21,22-10-6-3-7-11-22)16-17-28-18-20-12-14-23(28)15-13-20/h2-11,20,23H,12-18H2,1H3
SMILES Code
CC1=NN=C(C(C2=CC=CC=C2)(C3=CC=CC=C3)CCN4C(CC5)CCC5C4)O1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
387.52
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Brownsill RD, Hiley MP, Vose CW, Steiner JA, Stafford JE, McAllister A, Rose DA, Gerry N. Single- and multiple-dose pharmacokinetics of nufenoxole in healthy human subjects. Xenobiotica. 1987 Nov;17(11):1373-7. PubMed PMID: 3433806.
2: Moriarty KJ, Rolston DD, Kelly MJ, Shield M, Clark ML. Nufenoxole, a new antidiarrhoeal agent, inhibits fluid secretion in the human jejunum. Gut. 1985 Jan;26(1):75-80. PubMed PMID: 2578119; PubMed Central PMCID: PMC1432389.
3: Rachmilewitz D, Karmeli F. Effect of nufenoxole on human colonic prostanoid synthesis, Na-K-ATPase and adenylate cyclase activities. Eur J Pharmacol. 1984 Oct 30;106(1):153-8. PubMed PMID: 6152213.
4: Korey A, Zilm DH, Sellers EM. Dependence liability of two antidiarrheals, nufenoxole and loperamide. Clin Pharmacol Ther. 1980 May;27(5):659-64. PubMed PMID: 7371363.
5: Cook CS, Campion JG, Hribar JD, Karim A. Metabolism and pharmacokinetics of nufenoxole in animals and humans: an example of stereospecific hydroxylation of an isoquinuclidine ring. Xenobiotica. 1990 Oct;20(10):1065-80. PubMed PMID: 2082596.
6: Megens AA, Canters LL, Awouters FH, Niemegeers CJ. Is in vivo dissociation between the antipropulsive and antidiarrheal properties of opioids in rats related to gut selectivity? Arch Int Pharmacodyn Ther. 1989 Mar-Apr;298:220-9. PubMed PMID: 2569297.
